SEC Form 4 research
| Issuer | Outlook Therapeutics, Inc. |
|---|---|
| Tickers | ONS, OTLK |
| Reporting owners | 33 |
| Officers and directors | 14 |
| Last public filing | 2026-09-03 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-09-02 | 2026-09-01 | Lundquist Kevin Michael | A | 500,000 | $0 | Not reported |
| 2026-08-14 | 2026-08-14 | KENYON LAWRENCE A | P | 101,010 | Not reported | Not reported |
| 2026-08-14 | 2026-08-14 | KENYON LAWRENCE A | P | 101,010 | Not reported | Not reported |
| 2026-08-14 | 2026-08-14 | Jahr Robert Charles | P | 151,515 | Not reported | Not reported |
| 2026-08-14 | 2026-08-14 | Jahr Robert Charles | P | 151,515 | Not reported | Not reported |
| 2026-08-14 | 2026-08-12 | GMS Ventures & Investments, Sukhtian Ghiath M. | P | 2,525,252 | $0.99 | Not reported |
| 2026-08-14 | 2026-08-12 | GMS Ventures & Investments, Sukhtian Ghiath M. | P | 2,525,252 | $0 | Not reported |
| 2026-07-29 | 2026-07-29 | Sukhtian Faisal Ghiath | P | 95,398 | $1.05 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.